On September 16, 2024, William Hoffman, Director of Inari Medical Inc (NARI, Financial), sold 40,000 shares of the company. The transaction was filed on the same day with the SEC. Following this sale, the insider now owns 643,296 shares of Inari Medical Inc.
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from venous diseases. The company's innovative devices are designed to remove blood clots and restore blood flow, contributing to the rapidly growing field of vascular treatment.
Over the past year, William Hoffman has sold a total of 475,000 shares and has not made any purchases of the company's stock. This recent sale is part of a broader trend observed within the company, where there have been 33 insider sells and only 2 insider buys over the past year.
Shares of Inari Medical Inc were trading at $45.83 on the day of the sale. The company currently has a market cap of approximately $2.59 billion.
According to the GF Value, the intrinsic value of Inari Medical Inc is estimated at $88.92 per share, which suggests that the stock is currently undervalued with a price-to-GF-Value ratio of 0.52. This valuation indicates that the stock might be a Possible Value Trap, and investors should think twice before making an investment decision.
The GF Value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted for the company's past performance and expected future business outcomes.
This insider sale could provide valuable insights for current and potential investors, particularly in the context of the company's valuation and recent stock performance.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
